DelveInsight Business Research LLP
Albany, NY -- (SBWIRE) -- 12/06/2018 -- DelveInsight has announced the addition of the "Huntington's disease (HD)-Market Insights, Epidemiology and Market Forecast- 2027" drug pipelines to their offering.
The report provides an overview of the disease and market size of Huntington's Disease for the seven major markets i.e., United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the overview, treatment practice and forecasted epidemiology of Huntington's disease from 2016 to 2027 segmented by seven major markets.
Request for sample pages
Huntington's disease is a fatal genetic disorder that causes the progressive breakdown of nerve cells in the brain". It causes uncontrolled movements, emotional problems, and loss of thinking ability (cognition). Symptoms usually appear between the ages of 30 to 50 and worsen over a 10 to 25 year period. The disease is caused by a defective gene on chromosome 4 that causes an excessive build-up of the Huntington protein. This protein build-up damages nerve cells in parts of the brain, affecting neurological function, ultimately leads to Huntington's disease.
Each child of a Huntington disease parent has a 50-50 chance of inheriting the Huntington disease gene. Huntington disease affects 3 to 7 per 100,000 people of European ancestry. There are approximately 30,000 Americans, showing symptoms of Huntington's disease and more than 200,000 are at risk of inheriting the disease.
1. The United States
2. EU5 (Germany, France, Italy, Spain and the United Kingdom)
Study Period: 2016-2027
1. SOM Biotech SL
2. Vaccinex Inc.
3. Ionis Pharmaceuticals
4. Teva Pharmaceutical Industries
And many others
2. IONIS-HTTRx or (RG6042)
And many others
The report covers the descriptive overview of Huntington's Disease explaining its pathophysiology, disease classification, diagnostic approaches and treatment algorithm. The report provides the insight into the epidemiology of the disease and its treatment in the 7 MM covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan. The report is a comprehensive account of both the current and emerging therapies covering the impact of the new therapies on the current treatment landscape. The report also reviews the detailed historical and forecasted Huntington's Disease market size covering the drug outreach in 7MM. The report provides the understanding of the future competition in Huntington's Disease by reviewing the market drivers and barriers.